May 28 2004 12:05

# O

Date:

May 28, 2004

Number of pages (including cover): 4

To:

Office of Initial Patent Examination's Filing Receipt Corrections,

U.S. Patent and Trademark Office

Fax No.:

1-703-746-9195

Serial No.: 10/785,320

Title:

ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO

INDUCE LAXATION IN CHRONIC OPIOID USERS

From:

Edward R. Gates

Direct dial: 617.646.8232

Our File #: P0453.70113US03

### CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being transmitted via facsimile to the attention of Examiner Office of Initial Patent Examination's Filing Receipt Corrections, FAX number 1-703-746-9195, at the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, in accordance with 37 C.F.R. §1.6(d), on the 28th day of May, 2004.

ORIGINAL DOCUMENTS WILL NOT BE MAILED.

MESSAGE: Transmitted herewith are: Copy of Marked-Up Filing Receipt and Request for Correction of Filing Receipt .

This transmission contains confidential information intended for use only by the above-named recipient, Reading, discussing, distributing, or copying this message by anyone other than the named recipient, or his or her employees or agents, is strictly prohibited. If you have received this fax in error, please notify us immediately by telephone (collect), and return the original message to us at the address below via the U.S. Postal Service.

IF YOU DID NOT RECEIVE ALL OF THE PAGES OF THIS TRANSMISSION, OR IF ANY OF THE PAGES ARE ILLEGIBLE, PLEASE CALL 617.720.3500 IMMEDIATELY.

## Wolf Greenfield Fax Number: 617.720.2441

Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts 02210-2206 617.720.3500 | fax 617.720.2441 | www.wolfgreenfield.com

**PATENTS** 

TRADEMARKS COPYRIGHTS TECHNOLOGY TRANSFERS

**LITIGATION** 

796482 1

#### DOCKET NO: P0453.70113US03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Joseph F. Foss, et al.

Serial No:

10/785,320

Confirmation No:

9706

Filed:

February 24, 2004

For:

ORAL USE OF METHYLNALTREXONE AND RELATED

COMPOUNDS TO INDUCE LAXATION IN CHRONIC

OPIOID USERS

Examiner:

Not yet assigned

Art Unit:

1614

# CERTIFICATE OF FACSIMILE TRANSMISSION 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being transmitted via facsimile to the attention of Office of Initial Patent Examination's Filing Receipt Corrections, Fax number 1-703-746-9195, at the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, in accordance with 37 C.F.R.\_§ 1.6(d) on the 28th day of May, 2004.

Official of Initial Patent Examination's Filing Receipt Corrections Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

Please correct the filing receipt as indicated on the enclosed copy as outlined below.

Please correct the title to read as the following:

# -- ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO INDUCE LAXATION IN CHRONIC OPIOID USERS --

If you have any questions or need any assistance, please do not hesitate to call.

Respectfully submitted, Joseph F. Foss, et al., Applicant

Edward R. Gates, Reg. Np.: 31,616 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617) 646-8000

Docket No.: P0453.70113US03

Date: May 28, 2004

**xNDD**x 796480.1





# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Facest and Trademark Office Addrss COMMISSIONER FOR PATENTS FO. BOX 1409 Alexandris, Vicipita 22313-1430

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/785 320	02/24/2004	1614	530	P0453,70113US03	5	8	1

**CONFIRMATION NO. 9706** 

Edward R. Gates Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, MA 02210

FILING RECEIPT \*OC000000012674897\*

Date Mailed: 05/17/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Joseph F. Foss, Chicago, IL; Michael F. Roizen, Chicago, IL; Jonathan Moss, Chicago, IL; Chun-Su Yuan, Chicago, IL; William Drell, San Diego, CA, Deceased;

Initiale Confirmation Docketino

Domestic Priority data as claimed by applicant

This application is a CON of 10/357,669 02/04/2003 which is a CON of 09/669,358 09/26/2000 PAT 6,559,158 and is a CIP of 09/120,703 07/22/1998 PAT 6,274,591 which is a CIP of 08/962,742 11/03/1997 PAT 5,972,954

DOCKETED MAY 2 0 2004

Foreign Applications

if Required, Foreign Filing License Granted: 05/14/2004

.: •

Projected Publication Date: 08/26/2004 1135

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title '

Oral use of methylnal trexone and related compounds to induce laxation in chronic opioid users

ORAL USE OF METHYLNALTREKONE AND RELATED COMPOUNDS

Preliminary Class TO INDUCE LAXATION FN CHEONIC OPIOID USERS

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as Imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 8 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).